NASDAQ · Key Statistics

Tempest Therapeutics, Inc. (TPST) P/E Ratio, ROE & Key Statistics

$0.33 NASDAQ: TPST Market Cap $6.54M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Tempest Therapeutics, Inc. (TPST), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-0.10
P/B ratioShare price divided by book value per share.-3.53
P/S ratioMarket value divided by annual revenue.0.00
PEG ratioP/E divided by the earnings growth rate.0.00
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-0.35
EV / RevenueEnterprise value against annual revenue.0.00
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-1000.00%
Free cash flow yieldFree cash flow as a percentage of market value.-282.19%
Price / free cash flowMarket value divided by free cash flow.-0.35

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.0.00%
Operating marginRevenue left after operating costs.0.00%
Net marginRevenue left after every cost, including tax and interest.0.00%
Return on equityProfit as a percentage of shareholders’ equity.-371.43%
Return on assetsProfit as a percentage of total assets.-463.30%
Return on capital employedOperating profit against the capital the business uses.-974.32%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.0.34
Quick ratioThe same, excluding inventory.0.34
Cash ratioCash alone against current liabilities.2.67
Debt to equityTotal borrowings against shareholders’ equity.-3.97
Debt to assetsTotal borrowings against total assets.0.47
Interest coverageHow many times operating profit covers the interest bill.-48.09

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$6.33
Book value per shareShareholders’ equity divided by shares outstanding.−$0.11
Market capitalisationShare price times shares outstanding.$6.54M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$13.64M
EmployeesReported headcount.24

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Tempest Therapeutics, Inc. (TPST) statistics — frequently asked questions

What is Tempest Therapeutics, Inc.'s P/E ratio?

Tempest Therapeutics, Inc. (TPST) trades on a price-to-earnings ratio of -0.10. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Tempest Therapeutics, Inc.'s return on equity?

Tempest Therapeutics, Inc. (TPST) reports a return on equity of -371.43%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Tempest Therapeutics, Inc. carry?

Tempest Therapeutics, Inc. (TPST) has a debt-to-equity ratio of -3.97, which compares total borrowings with shareholders' equity.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.